The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
Sun Young JeongJung Yong HongJoon Oh ParkYoung Suk ParkHo Yeong LimJae Yeon JangYoungkyung JeonSeung Tae KimPublished in: Therapeutic advances in gastroenterology (2023)
Our analysis suggested that PD-L1 expression might be a useful biomarker for ICIs in BTC patients with KRAS mutation but not in those with wild-type KRAS.